Mark A Varney Selected Research

befiradol

1/2022	The selective 5-HT 1A receptor agonist, NLX-112, overcomes tetrabenazine-induced catalepsy and depression-like behavior in the rat.
1/2020	The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets.
10/2017	Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT1A receptor selective agonist, NLX-112 in mouse models of pain.
1/2016	The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark A Varney Research Topics

Disease

5	Dyskinesias (Dyskinesia) 01/2022 - 01/2016
2	Parkinson Disease (Parkinson's Disease) 01/2020 - 01/2016
2	Pain (Aches) 10/2017 - 06/2013
2	Neuralgia (Stump Neuralgia) 10/2017 - 06/2013
1	Obesity 04/2022
1	Catalepsy 01/2022
1	Chorea (Rheumatic Chorea) 01/2022
1	Motor Disorders 01/2022
1	Parkinsonian Disorders (Parkinsonism) 01/2022
1	Huntington Disease (Huntington's Disease) 01/2022
1	Anhedonia 11/2019
1	autosomal dominant Spastic paraplegia 6 01/2019
1	Acute Pain 10/2017
1	Diabetic Neuropathies (Diabetic Neuropathy) 10/2017
1	Peripheral Nervous System Diseases (PNS Diseases) 10/2017
1	Hyperalgesia 06/2013
1	Chronic Pain 06/2013
1	Major Depressive Disorder (Major Depressive Disorders) 03/2011
1	Weight Gain 04/2005
1	Mood Disorders (Mood Disorder) 11/2004
1	Shock 09/2002
1	Anxiety Disorders (Anxiety Disorder) 09/2002

Drug/Important Bio-Agent (IBA)

5	Levodopa (L Dopa)FDA LinkGeneric 01/2022 - 01/2016
5	5-HT1A Serotonin ReceptorIBA 01/2020 - 01/2016
4	Serotonin (5 Hydroxytryptamine)IBA 04/2022 - 03/2011
4	befiradolIBA 01/2022 - 01/2016
4	Dopamine (Intropin)FDA LinkGeneric 01/2020 - 03/2011
1	SugarsIBA 04/2022
1	AutoreceptorsIBA 04/2022
1	deutetrabenazineIBA 01/2022
1	Antidepressive Agents (Antidepressants)IBA 01/2022
1	Buspirone (Buspar)FDA LinkGeneric 01/2022
1	Tetrabenazine (Nitoman)FDA Link 01/2022
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2020
1	3- chloro- 4- fluorophenyl- (4- fluoro- 4- (((5- methylpyrimidin- 2- ylmethyl)amino)methyl)piperidin- 1- yl)methanoneIBA 11/2019
1	Sucrose (Saccharose)IBA 11/2019
1	Muscarinic M1 ReceptorIBA 01/2019
1	Histamine (Histamine Dihydrochloride)FDA Link 01/2019
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 10/2017
1	Formaldehyde (Formol)FDA Link 10/2017
1	Streptozocin (Streptozotocin)FDA Link 10/2017
1	PyrrolesIBA 06/2013
1	Serine (L-Serine)FDA Link 06/2013
1	Freund's AdjuvantIBA 06/2013
1	D-Amino-Acid Oxidase (D-Amino Acid Dehydrogenase)IBA 06/2013
1	Carboxylic AcidsIBA 06/2013
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 03/2011
1	Dexfenfluramine (Redux)IBA 04/2005
1	BenzodiazepinesIBA 11/2004
1	Ethanol (Ethyl Alcohol)IBA 11/2004
1	6-methyl-2-(phenylethynyl)pyridineIBA 09/2002
1	Anti-Anxiety Agents (Anxiolytics)IBA 09/2002
1	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA 09/2002

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 01/2020 - 10/2017
1	Oral Administration 06/2013
1	Ligation 06/2013
1	Induced Hyperthermia (Thermotherapy) 09/2002